Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2016

01-06-2016 | Review Article

Renal function trajectory over time and adverse clinical outcomes

Authors: Badrul Munir Sohel, Nahid Rumana, Masaki Ohsawa, Tanvir Chowdhury Turin, Martina Ann Kelly, Mohammad Al Mamun

Published in: Clinical and Experimental Nephrology | Issue 3/2016

Login to get access

Abstract

The growing burden of chronic kidney disease (CKD), with its associated morbidity and mortality, is recognized as a major public health problem globally and causing substantial load on health care systems. The current framework for the definition and staging of CKD, based on eGFR levels or presence of kidney damage, is useful for clinical classification of patients, but identifies a huge number of people as having CKD which is too many to target for intervention. The ability to identify a subset of patients, at high risk for adverse outcomes, would be useful to inform clinical management. The current staging system applies static definitions of kidney function that fail to capture the dynamic nature of the kidney disease over time. Now-a-days, it is possible to capture multiple measurements of different laboratory test results for an individual including eGFR values. A new possibility for identifying individuals at higher risk of adverse outcomes is being explored through assessment and consideration of the rate of change in kidney function over time, and this approach will be feasible in the current context of digitalization of health record keeping system. On the basis of the existing evidence, this paper summarizes important findings that support the concept of dynamic changes in kidney function over time, and discusses how the magnitude of these changes affect the future adverse outcomes of kidney disease, particularly the End Stage Renal Disease (ESRD), CVD and mortality.
Literature
1.
go back to reference Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–59. doi:10.1038/sj.ki.5002343.CrossRefPubMed Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–59. doi:10.​1038/​sj.​ki.​5002343.CrossRefPubMed
2.
go back to reference Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. doi:10.1016/s0140-6736(10)60674-5.CrossRefPubMedPubMedCentral Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. doi:10.​1016/​s0140-6736(10)60674-5.CrossRefPubMedPubMedCentral
3.
go back to reference Winearls CG. Chronic kidney disease: definition and staging–an orthodox view. Clin Med. 2009;9(6):563–4.CrossRef Winearls CG. Chronic kidney disease: definition and staging–an orthodox view. Clin Med. 2009;9(6):563–4.CrossRef
4.
go back to reference K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
5.
go back to reference Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25(10):567–79.CrossRefPubMedPubMedCentral Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25(10):567–79.CrossRefPubMedPubMedCentral
9.
go back to reference Smith HW. Diseases of the kidney and urinary tract in The Kidney: Structure and Function in Health and Disease. New York: Oxford University Press; 1951. Smith HW. Diseases of the kidney and urinary tract in The Kidney: Structure and Function in Health and Disease. New York: Oxford University Press; 1951.
12.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013(Suppl. 3):1–150. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013(Suppl. 3):1–150.
15.
go back to reference Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int. 2013;83(4):684–91. doi:10.1038/ki.2012.443.CrossRefPubMed Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int. 2013;83(4):684–91. doi:10.​1038/​ki.​2012.​443.CrossRefPubMed
16.
go back to reference Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012;27(10):3835–43. doi:10.1093/ndt/gfs263.CrossRefPubMed Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012;27(10):3835–43. doi:10.​1093/​ndt/​gfs263.CrossRefPubMed
17.
go back to reference Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. One-year change in kidney function is associated with an increased mortality risk. Am J Nephrol. 2012;36(1):41–9. doi:10.1159/000339289.CrossRefPubMed Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. One-year change in kidney function is associated with an increased mortality risk. Am J Nephrol. 2012;36(1):41–9. doi:10.​1159/​000339289.CrossRefPubMed
23.
go back to reference Leffondre K, Boucquemont J, Tripepi G, Stel VS, Heinze G, Dunkler D. Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches. Nephrol Dial Transplant. 2015;30(8):1237–43.CrossRefPubMed Leffondre K, Boucquemont J, Tripepi G, Stel VS, Heinze G, Dunkler D. Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches. Nephrol Dial Transplant. 2015;30(8):1237–43.CrossRefPubMed
24.
go back to reference Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31(3):433–41. doi:10.1291/hypres.31.433.CrossRefPubMed Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31(3):433–41. doi:10.​1291/​hypres.​31.​433.CrossRefPubMed
25.
go back to reference Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO, Jenssen T. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant. 2008;23(9):2818–26. doi:10.1093/ndt/gfn148.CrossRefPubMed Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO, Jenssen T. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant. 2008;23(9):2818–26. doi:10.​1093/​ndt/​gfn148.CrossRefPubMed
26.
go back to reference Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004;43(1):112–9.CrossRefPubMed Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004;43(1):112–9.CrossRefPubMed
27.
go back to reference Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26(6):861–8.CrossRefPubMed Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26(6):861–8.CrossRefPubMed
28.
go back to reference Slack TK, Wilson DM. Normal renal function: CIN and CPAH in healthy donors before and after nephrectomy. Mayo Clin Proc. 1976;51(5):296–300.PubMed Slack TK, Wilson DM. Normal renal function: CIN and CPAH in healthy donors before and after nephrectomy. Mayo Clin Proc. 1976;51(5):296–300.PubMed
29.
go back to reference Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31(2):155–63.CrossRefPubMed Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31(2):155–63.CrossRefPubMed
32.
go back to reference Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21(8):2133–43. doi:10.1093/ndt/gfl198.CrossRefPubMed Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21(8):2133–43. doi:10.​1093/​ndt/​gfl198.CrossRefPubMed
33.
go back to reference Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–31.CrossRefPubMed Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–31.CrossRefPubMed
34.
go back to reference Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877–84. doi:10.1056/nejm199403313301301.CrossRefPubMed Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877–84. doi:10.​1056/​nejm199403313301​301.CrossRefPubMed
35.
go back to reference Levey AS, Gassman JJ, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol. 1991;1(9):1087–94.PubMed Levey AS, Gassman JJ, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol. 1991;1(9):1087–94.PubMed
38.
go back to reference Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17(9):2582–90. doi:10.1681/asn.2005121352.CrossRefPubMed Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17(9):2582–90. doi:10.​1681/​asn.​2005121352.CrossRefPubMed
40.
go back to reference Al-Aly Z, Cepeda O. Rate of change in kidney function and the risk of death: the case for incorporating the rate of kidney function decline into the CKD staging system. Nephron Clin Pract. 2011;119(2):c179–85. doi:10.1159/000324768 (discussion c86). Al-Aly Z, Cepeda O. Rate of change in kidney function and the risk of death: the case for incorporating the rate of kidney function decline into the CKD staging system. Nephron Clin Pract. 2011;119(2):c179–85. doi:10.​1159/​000324768 (discussion c86).
42.
43.
go back to reference Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9(1):13–25. doi:10.1054/jcaf.2003.3.CrossRefPubMed Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9(1):13–25. doi:10.​1054/​jcaf.​2003.​3.CrossRefPubMed
44.
go back to reference Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the multiple risk factor intervention trial and the treatment of mild hypertension study. Am J Kidney Dis. 1993;21(4 Suppl 1):31–40.CrossRefPubMed Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the multiple risk factor intervention trial and the treatment of mild hypertension study. Am J Kidney Dis. 1993;21(4 Suppl 1):31–40.CrossRefPubMed
45.
go back to reference Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;. doi:10.1001/jama.2014.6634. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;. doi:10.​1001/​jama.​2014.​6634.
46.
go back to reference Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47–55.CrossRefPubMed Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47–55.CrossRefPubMed
47.
go back to reference Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5):1307–15.CrossRefPubMed Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5):1307–15.CrossRefPubMed
48.
go back to reference Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis. 2004;43(5):861–7.CrossRefPubMed Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis. 2004;43(5):861–7.CrossRefPubMed
49.
go back to reference Odden MC, Chertow GM, Fried LF, Newman AB, Connelly S, Angleman S, et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol. 2006;164(12):1180–9. doi:10.1093/aje/kwj333.CrossRefPubMed Odden MC, Chertow GM, Fried LF, Newman AB, Connelly S, Angleman S, et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol. 2006;164(12):1180–9. doi:10.​1093/​aje/​kwj333.CrossRefPubMed
52.
go back to reference Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60(3):1131–40.CrossRefPubMed Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60(3):1131–40.CrossRefPubMed
53.
go back to reference Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165(8):947–53.CrossRefPubMed Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165(8):947–53.CrossRefPubMed
54.
go back to reference Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002;17(7):1197–203.CrossRefPubMed Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002;17(7):1197–203.CrossRefPubMed
55.
go back to reference Saweirs WW, Goddard J. What are the best treatments for early chronic kidney disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant. 2007;22(9):ix31–8. Saweirs WW, Goddard J. What are the best treatments for early chronic kidney disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant. 2007;22(9):ix31–8.
56.
go back to reference McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scott Med J. 1997;42(4):99–104.PubMed McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scott Med J. 1997;42(4):99–104.PubMed
57.
go back to reference Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996;5(3):219–23.CrossRefPubMed Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996;5(3):219–23.CrossRefPubMed
58.
go back to reference Berrut G, Bouhanick B, Fabbri P, Guilloteau G, Bled F, Le Jeune JJ, et al. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin Nephrol. 1997;48(2):92–7.PubMed Berrut G, Bouhanick B, Fabbri P, Guilloteau G, Bled F, Le Jeune JJ, et al. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin Nephrol. 1997;48(2):92–7.PubMed
59.
go back to reference Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med. 2007;167(13):1386–92.CrossRefPubMed Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med. 2007;167(13):1386–92.CrossRefPubMed
61.
go back to reference Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821–35.CrossRefPubMed Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821–35.CrossRefPubMed
62.
go back to reference Kovesdy CP. Rate of kidney function decline associates with increased risk of death. J Am Soc Nephrol. 2010;21(11):1814–6.CrossRefPubMed Kovesdy CP. Rate of kidney function decline associates with increased risk of death. J Am Soc Nephrol. 2010;21(11):1814–6.CrossRefPubMed
63.
go back to reference Weldegiorgis M, de Zeeuw D, Heerspink HJ. Renal end points in clinical trials of kidney disease. Curr Opin Nephrol Hypertens. 2015;24(3):284–9.PubMed Weldegiorgis M, de Zeeuw D, Heerspink HJ. Renal end points in clinical trials of kidney disease. Curr Opin Nephrol Hypertens. 2015;24(3):284–9.PubMed
64.
go back to reference Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59(4):504–12.CrossRefPubMedPubMedCentral Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59(4):504–12.CrossRefPubMedPubMedCentral
65.
go back to reference Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553–9.CrossRefPubMed Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553–9.CrossRefPubMed
66.
go back to reference Rosansky SJ. Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease. Am J Nephrol. 2012;36(1):1–10.CrossRefPubMed Rosansky SJ. Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease. Am J Nephrol. 2012;36(1):1–10.CrossRefPubMed
Metadata
Title
Renal function trajectory over time and adverse clinical outcomes
Authors
Badrul Munir Sohel
Nahid Rumana
Masaki Ohsawa
Tanvir Chowdhury Turin
Martina Ann Kelly
Mohammad Al Mamun
Publication date
01-06-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1213-0

Other articles of this Issue 3/2016

Clinical and Experimental Nephrology 3/2016 Go to the issue